James K. Gabriels

Dr. James K. Gabriels


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
PDF file
MSMoussa Saleh
Moussa Saleh
JGJames K. Gabriels
James K. Gabriels
DCDavid Chang
David Chang
BKBeom Soo Kim
Beom Soo Kim
AMAmtul Mansoor
Amtul Mansoor
LELaurence M. Epstein
Laurence M. Epstein
Background: The novel SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is responsible for the global coronavirus disease 2019 pandemic. Small studies have shown a potential benefit of chloroquine/hydroxychloroquine±azithromycin for the treatment of coronavirus disease 2019. Use of these medications alone, or in combination, can lead to a prolongation of the QT interval, possibly increasing the risk of Torsade de pointes and sudden cardiac death. Methods: Hospitalized patients treated with chloroquine/hydroxychloroquine±azithromycin from March 1 to the 23 at 3 hospitals within the Northwell Health system were included in this prospective, observational study. Serial assessments of the QT interval were performed. The primary outcome was QT prolongation resulting in Torsade de pointes. Secondary outcomes included QT prolongation, the need to prematurely discontinue any of the medications due to QT prolongation, and arrhythmogenic death. Results: Two hundred one patients were treated for coronavirus disease 2019 with chloroquine/hydroxychloroquine. Ten patients (5.0%) received chloroquine, 191 (95.0%) received hydroxychloroquine, and 119 (59.2%) also received azithromycin. The primary outcome of torsade de pointes was not observed in the entire population. Baseline corrected QT interval intervals did not differ between patients treated with chloroquine/hydroxychloroquine (monotherapy group) versus those treated with combination group (chloroquine/hydroxychloroquine and azithromycin; 440.6±24.9 versus 439.9±24.7 ms, P =0.834). The maximum corrected QT interval during treatment was significantly longer in the combination group versus the monotherapy group (470.4±45.0 ms versus 453.3±37.0 ms, P =0.004). Seven patients (3.5%) required discontinuation of these medications due to corrected QT interval prolongation. No arrhythmogenic deaths were reported. Conclusions: In the largest reported cohort of coronavirus disease 2019 patients to date treated with chloroquine/hydroxychloroquine±azithromycin, no instances of Torsade de pointes, or arrhythmogenic death were reported. Although use of these medications resulted in QT prolongation, clinicians seldomly needed to discontinue therapy. Further study of the need for QT interval monitoring is needed before final recommendations can be made.

12 February 2020 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
DCDavid Chang
David Chang
JGJames K. Gabriels
James K. Gabriels
BKBeom Soo Kim
Beom Soo Kim
HIHaisam Ismail
Haisam Ismail
JWJonathan Willner
Jonathan Willner
LELaurence M. Epstein
Laurence M. Epstein

29 September 2023 in EP Europace
Verified
Journal Article
Open access
PDF file
JGJames K. Gabriels
James K. Gabriels
RSRobert D Schaller
Robert D Schaller
EKElana Koss
Elana Koss
BRBruce J Rutkin
Bruce J Rutkin
RCRoger G Carrillo
Roger G Carrillo
LELaurence M Epstein
Laurence M Epstein
Clinically significant tricuspid regurgitation (TR) has historically been managed with either medical therapy or surgical interventions. More recently, percutaneous trans-catheter tricuspid valve (TV) replacement and tricuspid trans-catheter edge-to-edge repair have emerged as alternative treatment modalities. Patients with cardiac implantable electronic devices (CIEDs) have an increased incidence of TR. Severe TR in this population can occur for multiple reasons but most often results from the interactions between the CIED lead and the TV apparatus. Management decisions in patients with CIED leads and clinically significant TR, who are undergoing evaluation for a percutaneous TV intervention, need careful consideration as a trans-venous lead extraction (TLE) may both worsen and improve TR severity. Furthermore, given the potential risks of ‘jailing’ a CIED lead at the time of a percutaneous TV intervention (lead fracture and risk of subsequent infections), consideration should be given to performing a TLE prior to a percutaneous TV intervention. The purpose of this ‘state-of-the-art’ review is to provide an overview of the causes of TR in patients with CIEDs, discuss the available therapeutic options for patients with TR and CIED leads, and advocate for including a lead management specialist as a member of the ‘heart team’ when making treatment decisions in patients TR and CIED leads.

1 May 2020 in HeartRhythm Case Reports
Verified
Journal Article
Open access
JGJames K. Gabriels
James K. Gabriels
MSMoussa Saleh
Moussa Saleh
DCDavid Chang
David Chang
LELaurence M. Epstein
Laurence M. Epstein

1 March 2021 in Heart Rhythm
Verified
Journal Article
Closed access
JGJames K. Gabriels
James K. Gabriels
DCDavid Chang
David Chang
MMMelanie Maytin
Melanie Maytin
TTThomas Tadros
Thomas Tadros
RJRoy M. John
Roy M. John
LELaurence M. Epstein
Laurence M. Epstein

1 April 2018 in Heart Rhythm
Verified
Journal Article
Closed access
MWMichael Wu
Michael Wu
JGJames K. Gabriels
James K. Gabriels
MKMohammad Khan
Mohammad Khan
NSNada Shaban
Nada Shaban
SDSalvatore D'AMato
Salvatore D'AMato
JCJim W. Cheung
Jim W. Cheung